![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZBTB45 |
Gene summary for ZBTB45 |
![]() |
Gene information | Species | Human | Gene symbol | ZBTB45 | Gene ID | 84878 |
Gene name | zinc finger and BTB domain containing 45 | |
Gene Alias | ZNF499 | |
Cytomap | 19q13.43 | |
Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | A0A024R4T8 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84878 | ZBTB45 | P79T-E | Human | Esophagus | ESCC | 2.46e-21 | 3.23e-01 | 0.1154 |
84878 | ZBTB45 | P80T-E | Human | Esophagus | ESCC | 1.49e-11 | 2.49e-01 | 0.155 |
84878 | ZBTB45 | P82T-E | Human | Esophagus | ESCC | 3.85e-08 | 4.21e-01 | 0.1072 |
84878 | ZBTB45 | P83T-E | Human | Esophagus | ESCC | 5.55e-29 | 7.09e-01 | 0.1738 |
84878 | ZBTB45 | P84T-E | Human | Esophagus | ESCC | 9.24e-04 | 2.12e-01 | 0.0933 |
84878 | ZBTB45 | P91T-E | Human | Esophagus | ESCC | 4.77e-06 | 3.30e-01 | 0.1828 |
84878 | ZBTB45 | P107T-E | Human | Esophagus | ESCC | 3.97e-15 | 3.10e-01 | 0.171 |
84878 | ZBTB45 | P126T-E | Human | Esophagus | ESCC | 8.52e-04 | 3.92e-01 | 0.1125 |
84878 | ZBTB45 | P127T-E | Human | Esophagus | ESCC | 5.97e-10 | 7.46e-02 | 0.0826 |
84878 | ZBTB45 | P128T-E | Human | Esophagus | ESCC | 4.19e-11 | 2.89e-01 | 0.1241 |
84878 | ZBTB45 | P130T-E | Human | Esophagus | ESCC | 5.47e-08 | 1.94e-01 | 0.1676 |
Page: 1 2 3 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![]() | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias | ||
LGIN: Low-grade intraepithelial neoplasias |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZBTB45 | SNV | Missense_Mutation | c.328N>T | p.Arg110Cys | p.R110C | Q96K62 | protein_coding | deleterious(0) | probably_damaging(0.958) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
ZBTB45 | SNV | Missense_Mutation | novel | c.316N>A | p.Ala106Thr | p.A106T | Q96K62 | protein_coding | deleterious(0) | probably_damaging(0.922) | TCGA-EA-A3HR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZBTB45 | SNV | Missense_Mutation | c.1277N>T | p.Ser426Leu | p.S426L | Q96K62 | protein_coding | deleterious(0) | possibly_damaging(0.697) | TCGA-IR-A3LB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
ZBTB45 | SNV | Missense_Mutation | rs750055767 | c.530N>T | p.Ala177Val | p.A177V | Q96K62 | protein_coding | tolerated(1) | benign(0.074) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
ZBTB45 | SNV | Missense_Mutation | rs747624433 | c.118C>T | p.Arg40Cys | p.R40C | Q96K62 | protein_coding | deleterious(0) | benign(0.015) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
ZBTB45 | SNV | Missense_Mutation | c.1201N>T | p.Pro401Ser | p.P401S | Q96K62 | protein_coding | tolerated(0.17) | benign(0.001) | TCGA-A6-6780-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ZBTB45 | SNV | Missense_Mutation | rs778329030 | c.1244N>A | p.Arg415Gln | p.R415Q | Q96K62 | protein_coding | deleterious(0.01) | probably_damaging(0.909) | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ZBTB45 | SNV | Missense_Mutation | novel | c.1159N>C | p.Ala387Pro | p.A387P | Q96K62 | protein_coding | tolerated(0.15) | possibly_damaging(0.462) | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD |
ZBTB45 | SNV | Missense_Mutation | c.1130T>C | p.Val377Ala | p.V377A | Q96K62 | protein_coding | tolerated(1) | benign(0) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZBTB45 | SNV | Missense_Mutation | novel | c.835N>A | p.Ala279Thr | p.A279T | Q96K62 | protein_coding | tolerated(0.51) | benign(0) | TCGA-AG-4008-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |